Cambium Bio
Focus: Cambium Bio is an early-stage Australian biotech company founded in 2024, specializing in platelet-based therapies and cell growth supplements for oncology and hematology indications. The company is publicly listed but pre-revenue with a minimal clinical footprint.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Cambium Bio
AI assessmentNot HiringNo open roles listed right now. Follow Cambium Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CAM-101 10%
Dry EyeCAM-101
Dry Eye DiseaseOpen Jobs (0)
Help build intelligence for Cambium Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.